(Q46946161)

26 December 2017

title

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma (English)

1 reference

26 December 2017

0 references

1 reference

1 reference

7

1 reference

26 December 2017

Michele Cavo

Michele Cavo

12

0 references

Michele Baccarani

11

Michele Baccarani

1 reference

26 December 2017

2

Elena Zamagni

1 reference

26 December 2017

Paola Tacchetti

6

Paola Tacchetti

1 reference

26 December 2017

Patrizia Tosi

1

Patrizia Tosi

1 reference

26 December 2017

Claudia Cellini

3

Claudia Cellini

1 reference

26 December 2017

Delia Cangini

5

Delia Cangini

1 reference

26 December 2017

Michela Ceccolini

8

Michela Ceccolini

1 reference

26 December 2017

author name string

Raffaele Parente

4

1 reference

26 December 2017

Paola Boni

9

1 reference

26 December 2017

Sante Tura

10

1 reference

26 December 2017

publication date

15 February 2006

1 reference

26 December 2017

European Journal of Haematology

published in

1 reference

26 December 2017

volume

76

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

399-404

1 reference

26 December 2017

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0902-4441.2005.T01-1-EJH2520.X

10.1111/J.0902-4441.2005.T01-1-EJH2520.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017